On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...

Primary results from ResMed Inc.’s RMD CAT-HF trial showcased the significance of adaptive servo-ventilation (ASV) therapy in the treatment of heart failure (HF). Data were presented at the European ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: SERVE-HF ...

On Jun 19, 2015, we issued an updated research report on ResMed, Inc. RMD. Recently, ResMed faced a major blow as its phase III SERVE-HF study of ASV failed to meet its primary endpoint. In fact, the ...

Cardiovascular problems can be associated with sleep apnea, and it's commonly assumed that treatment of sleep apnea could have cardiovascular benefits. But a ResMed ...

ResMed has struggled to bounce back from the shock failure of a clinical trial in May, which pushed its shares down 18 per cent, and it is still trading down more than 11 per cent on its May price.

SAN DIEGO, May 13, 2015 /CNW/ -- ResMed (NYSE: RMD) today announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint. SERVE-HF was ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

- Safety Signal of Increased Cardiovascular Mortality Found For ASV Therapy In People With Predominant Central Sleep Apnea and Symptomatic Chronic Heart Failure - Results and Safety Signal Observed ...